Programmaschema Chicago op Schier 2023 – dinsdag 6 juni

zie hyperlinks hieronder voor de vervolgdagen

Dinsdag 6 juni 2023

08.30 uur Virtual ASCO – Locatie: Dorpshuis

Educational: Prioritizing and sequencing for advanced prostate cancer

  1. N. Agarwal When More Is More: Treatment Intensification for Hormone-Sensitive Prostate Cancer 
  2. A. Hamid When Less Is More: Decreasing Exposure to Systemic Therapy for Hormone-Sensitive Prostate Cancer 

Educational: Management of prostate cancer in older adults

  1. A. Morgans Applying Risk/Benefit Considerations for Elder Patients to Current Treatment Advances in Prostate Cancer

Educational: bringing new drugs in oncology: Incorporation into practice

  1. K. Fizazi Taking Radioligands to the Next Level: Targeting PSMA with Lutetium 177

Oral Abstract Session Genitourinary Cancer—Prostate + discussants (zondag 04-06 08.00-11.00)

  1. A. Bossi Prostate irradiation in men with de novo, low-volume, metastatic, castration-sensitive prostate cancer (mCSPC): Results of PEACE-1, a phase 3 randomized trial with a 2×2 design Abs#LBA5000
  2. K. Fizazi TALAPRO-2: Phase 3 study of talazoparib (TALA) + enzalutamide (ENZA) versus placebo (PBO) + ENZA as first-line (1L) treatment for patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) harboring homologous recombination repair (HRR) gene alterations Abs#5004

10.00 uur Pauze

10.15 uur Virtual ASCO – Locatie: Dorpshuis

Educational Managing a long and winding road: ER-positive breast cancer

N. Turner Using CDK4/6 Inhibitor in Early Stage and Advanced HR+ Breast Cancer

Oral abstract session breast cancer local/adjuvant

  1. D. Slamon Ribociclib and endocrine therapy as adjuvant treatment in patients with HR+/HER2− early breast cancer: Primary results from the phase III NATALEE trial Abs#LBA500
  2. E. Hamilton Efficacy and safety results by age in monarchE: Adjuvant abemaciclib combined with endocrine therapy (ET) in patients with HR+, HER2-, node-positive, high-risk early breast cancer (EBC) Abs#501
  3. N. Harbeck Cyclin’ Through the Inhibitors Abstracts discussant
  4. Z. Jiang TORCHLIGHT: A randomized, double-blind, phase III trial of toripalimab versus placebo, in combination with nab-paclitaxel(nab-P) for patients with metastatic or recurrent triple-negative breast cancer (TNBC) Abs#LBA1013

Educational: Improving quality of life on chemotherapy for patients with breast cancer: realistic of wishful thinking?

M. Accordino Mitigating Neuropathy: Cooling Down and Other Options

Poster session Colorectal maandag

Miriam Koopman Upfront palliative resection of primary tumor versus no resection in patients with synchronous metastatic colorectal cancer: The randomized phase 3 CAIRO4 study of the Dutch Colorectal Cancer Group (DCCG. Abs#3517

A. Kim The Evolving Role of Surgery in Advanced Colorectal Cancer

12.00 -14:00 uur pauze – Lunch, Havenpaviljoen Wad Anderz, Reeweg 25

14.00 uur Virtual ASCO, locatie: Dorpshuis

Educational: A juggling act: Managing the toxicity of estrogen deprivation for patients with breast cancer

  1. Rojas Better Sexual Health for Female Patients on Endocrine Therapy: Strategies Across the Age Spectrum
  2. Woodard Innovations in Fertility: Are We Where We Want to Be? 

Oral abstract session breast cancer metastatic

  1. E. Hamilton A phase 2 study of HER3-DXd in patients (pts) with metastatic breast cancer (MBC) Abs#1004
  2. I. Krop An age-specific pooled analysis of trastuzumab deruxtecan (T‑DXd) in patients (pts) with HER2-positive (HER2+) metastatic breast cancer (mBC) from DESTINY-Breast01, -02, and -03 Abs#1006

14.45-15.00 uur Pauze

  1. S. Tolaney Final overall survival (OS) analysis from the phase 3 TROPiCS-02 study of sacituzumab govitecan (SG) in patients (pts) with hormone receptor–positive/HER2-negative (HR+/HER2–) metastatic breast cancer (mBC) Abs#1003
  2. Q. Khan Randomized trial of fixed dose capecitabine compared to standard dose capecitabine in metastatic breast cancer: The X-7/7 trial Abs#1007
  3. Gabe Sonke Primary outcome analysis of the phase 3 SONIA trial (BOOG 2017-03) on selecting the optimal position of cyclin-dependent kinases 4 and 6 (CDK4/6) inhibitors for patients with hormone receptor-positive (HR+), HER2-negative (HER2-) advanced breast cancer (ABC) Abs#LBA1000
  4. A. Llombart Second-line endocrine therapy (ET) with or without palbociclib (P) maintenance in patients (pts) with hormone receptor-positive (HR[+])/human epidermal growth factor receptor 2-negative (HER2[-]) advanced breast cancer (ABC): PALMIRA trial Abs# 1001
  5. D. Stover Seeking Sensitivity and Resisting Resistance: Learning From the CDK4/6 Experience Abstracts discussant

16.30 uur: Live verbinding met Chicago – Gabe Sonke

17.30 uur Pauze + teruglopen naar Van der Werff

17.45 uur Klinische implicaties olv referent (besloten) – Locatie: vd Werff

18.30 uur Einde middagprogramma

19.30 uur BBQ in Beachclub Noderstraun, Badweg 32

Woensdag 7 juni 2023
Maandag 5 juni 2023
Zondag 4 juni 2023

© Copyright 2023 - Congress Care - Website door Lemone